EP Patent

EP3565819B1 — Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate

Assigned to F Hoffmann La Roche AG · Expires 2025-11-19 · 0y expired

What this patent protects

Patent listed against deuruxolitinib-phosphate.

Drugs covered by this patent

deuruxolitinib-phosphate (DEURUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: EP3565819B1
Jurisdiction: EP
Classification: —
Expires: 2025-11-19
Drug substance claim: No
Drug product claim: No
Assignee: F Hoffmann La Roche AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.